<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lithium: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lithium: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lithium: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10813" href="/d/html/10813.html" rel="external">see "Lithium: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12559" href="/d/html/12559.html" rel="external">see "Lithium: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709018"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Monitoring:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24520178"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Lithobid</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867385"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Lithium Carbonate;</li>
<li>Carbolith;</li>
<li>DOM-Lithium Carbonate;</li>
<li>Lithane;</li>
<li>Lithmax;</li>
<li>PMS-Lithium Carbonate</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F189386"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antimanic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F189348"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Only prescribe in settings where serum concentration monitoring is available. Toxic effects occur with serum concentrations ≥1.5 mEq/L and may be seen in some patients with serum concentrations as low as 1.2 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Janicak.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Janicak.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> All doses in this monograph are expressed as the equivalent amounts of lithium carbonate salt. Initial dosing frequency varies by formulation; however, if initial dose is ≤300 mg/day, may initiate as once daily regardless of formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gitlin.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gitlin.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Lithium citrate 5 mL (8 mEq) oral solution is equivalent to carbonate 300 mg tablets/capsules. Lithium oral solution has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1969751f-c027-4072-874e-d4df29195cbe">Bipolar disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder (monotherapy or combination therapy):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Acute mania, acute episodes with mixed features (labeled use), acute hypomania (off-label use), or acute bipolar major depression (alternative agent) (off-label use): </b>For most patients, a therapeutic response occurs with serum concentrations between 0.8 and 1.2 mEq/L; some respond to lower levels (eg, 0.6 mEq/L). For treatment of acute severe mania, typically given in combination with an antipsychotic or antiseizure drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616','lexi-content-ref-Janicak.2020','lexi-content-ref-Stovall.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616','lexi-content-ref-Janicak.2020','lexi-content-ref-Stovall.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Immediate release or extended release<b>: </b>Initial: 600 to 900 mg/day in 2 to 3 divided doses based on chosen formulation (initially administer IR daily dose in 2 to 3 divided doses and ER daily dose in 2 divided doses); increase based on response and tolerability by 300 to 600 mg every 1 to 5 days to usual therapeutic dose range of 900 mg/day to 1.8 g/day in 1 to 3 divided doses based on tolerability or chosen formulation. After 5 to 7 days at a stable therapeutic dose, further adjust as needed based on clinical response, tolerability, and serum concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16263857','lexi-content-ref-Janicak.2020','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16263857','lexi-content-ref-Janicak.2020','lexi-content-ref-manu.1'])">Ref</a></span>). <b>Note: </b>After several weeks at an established dose and stable serum concentrations, may consolidate schedule to a single dose of immediate release or extended release at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24165107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24165107'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Maintenance treatment to prevent manic or depressed episodes:</b>
<b>Note: </b>Continue regimen (ie, monotherapy or combination) that was used to achieve control of the acute episode; a lower dose and serum concentration at the lower end of the therapeutic range may suffice for some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21834235-a609-461a-9235-1108c4282c97">Major depressive disorder, unipolar</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder, unipolar (alternative agent; adjunctive therapy) (off-label use): </b>For most patients, a therapeutic response occurs with serum concentrations between 0.6 and 1.2 mEq/L; some respond to lower serum concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gitlin.2021','lexi-content-ref-16946176']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gitlin.2021','lexi-content-ref-16946176'])">Ref</a></span>). Peak clinical improvement may take up to 6 weeks when lithium is used for antidepressant augmentation for acute depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2020','lexi-content-ref-8149115']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2020','lexi-content-ref-8149115'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release or extended release: Initial: 300 to 600 mg/day in 1 to 2 divided doses; if initial dose is ≤300 mg/day, may initiate as once daily regardless of formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gitlin.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gitlin.2021'])">Ref</a></span>); may increase based on response and tolerability every 1 to 5 days to a target dose of 600 mg to 1.2 g/day in 1 to 3 divided doses based on tolerability or chosen formulation (administer IR daily dose in 2 to 3 divided doses and ER daily dose in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12971013','lexi-content-ref-Gitlin.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12971013','lexi-content-ref-Gitlin.2021'])">Ref</a></span>)). <b>Note: </b>After several weeks at an established dose and stable serum concentrations, may consolidate schedule to a single dose of immediate release or extended release at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24165107']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24165107'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosing conversion: </b>To convert between IR and ER capsules/tablets, administer the same total daily dose. Initially administer IR daily dose in 2 to 3 divided doses and ER daily dose in 2 divided doses. If initial dose is ≤300 mg/day, may initiate as once daily regardless of formulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gitlin.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gitlin.2021'])">Ref</a></span>). After several weeks at an established dose, may consolidate schedule to a single dose of immediate release or extended release at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24165107','lexi-content-ref-Janicak.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24165107','lexi-content-ref-Janicak.2020'])">Ref</a></span>). When taken as a single dose per day, serum trough concentrations are 10% to 26% higher compared to serum trough concentrations with divided doses, due to changes in renal excretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11564052','lexi-content-ref-20592663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11564052','lexi-content-ref-20592663'])">Ref</a></span>). Individual dosage adjustments may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy: </b>Gradual dose reduction is advised to avoid disease recurrence unless discontinuation is due to significant adverse effects. If it is necessary to switch to a different drug during acute treatment, decrease the lithium dose over 1 to 2 weeks (eg, by 300 mg each day or every other day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kupka.2020','lexi-content-ref-Stovall.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kupka.2020','lexi-content-ref-Stovall.2021'])">Ref</a></span>). In order to detect disease recurrence when discontinuing maintenance treatment for bipolar disorder, decrease lithium over several weeks to months when feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Post.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Post.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991625"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Lithium is primarily excreted via the kidneys and clearance correlates directly with glomerular filtration rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1769139','lexi-content-ref-2805595']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1769139','lexi-content-ref-2805595'])">Ref</a></span>). Because of the risk of lithium-related nephrotoxicity, routine monitoring of serum lithium levels and kidney function are recommended in patients with reduced kidney function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25519823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25519823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Oral: </b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥60 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to &lt;60 mL/minute: Initiate at low doses (eg, 150 to 300 mg/day) in 1 to 2 divided doses, titrate slowly based on clinical response and tolerability, monitor levels frequently (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> No data available. Consider dose adjustments based on serum lithium levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialyzable (up to 80% removed from extracellular fluid; however, lithium remains in tissue and significant increases in lithium concentration [also known as "rebound"] occur as lithium equilibrates from tissue compartments into the blood stream) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30748087']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30748087'])">Ref</a></span>); lithium levels drawn immediately post hemodialysis will be inaccurate/falsely low:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Avoid use when possible. Consider use of an alternative therapy, especially in patients with significant residual kidney function due to risk of lithium-induced kidney damage. If necessary, initiate therapy at 300 mg 3 times weekly after dialysis; gradually titrate based on clinical response, tolerability, and serum lithium levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30748087','lexi-content-ref-34176305','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30748087','lexi-content-ref-34176305','lexi-content-ref-Expert.DOR'])">Ref</a></span>). In some patients, daily dosing may be required to achieve targeted lithium serum levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30748087','lexi-content-ref-34176305']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30748087','lexi-content-ref-34176305'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Dialyzable (less than hemodialysis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7259950','lexi-content-ref-5090765']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7259950','lexi-content-ref-5090765'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Avoid use when possible. Consider use of an alternative therapy, especially in patients with significant residual kidney function due to risk of lithium-induced kidney damage. If necessary, start at low dose (eg, 150 mg daily); gradually titrate based on clinical response, tolerability, and serum lithium levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations and consideration of initial loading doses. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988907"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F189349"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">
<b>Bipolar disorder</b>: Initiate therapy with lower doses; refer to adult dosing. Some guidelines recommend lower target serum concentrations (eg, 0.4 to 0.8 mEq/L for older adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29536616']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29536616'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F189366"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12559" href="/d/html/12559.html" rel="external">see "Lithium: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Each 5 mL of lithium citrate oral solution contains 8 mEq of lithium ion, equivalent to the amount of lithium in 300 mg of lithium carbonate immediate-release capsules/tablets. Lithium oral solution has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1969751f-c027-4072-874e-d4df29195cbe">Bipolar disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder:</b>
<b>Note:</b> Monitor serum concentrations and clinical response (efficacy and toxicity) to determine proper dose. For acute therapy of pediatric bipolar disorder (acute manic/mixed episodes without psychosis), lithium has been suggested as augmentation therapy with a second-generation antipsychotic (SGA) (due to decreased suicidality) or as monotherapy if a trial of two different SGAs lacks adequate response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31369795','lexi-content-ref-36472471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31369795','lexi-content-ref-36472471'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release:</i> Children ≥7 years and Adolescents: Limited data available in weight &lt;20 kg: <b>Note: </b>Dosing in weight &lt;20 kg extrapolated from clinical experience (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gal.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gal.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Lithium carbonate capsule or tablet:</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight &lt;30 kg: Oral: Initial: 300 mg twice daily, increase dose at weekly intervals in 300 mg/day increments as tolerated to clinical response and goals based on type of therapy (acute or maintenance).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Acute therapy</i>: Oral: Titrate dose to 600 to 1,500 mg/day in divided doses and target serum lithium concentration of 0.8 to 1.2 mEq/L; a maximum dose is not described in the manufacturer labeling; in trials, weight-dependent maximum daily doses were reported: Patients &lt;23 kg: 900 mg/<b>day</b>; patients ≥23 kg: 40 mg/kg/<b>day</b> and doses were not further increased if serum lithium concentration was ≥1.4 mEq/L. In a multicenter, double-blind, placebo-controlled efficacy trial for treatment of acute mania, the mean effective daily dose was 956 ± 225 mg/<b>day</b>. For all patients in the trial (regardless of weight) the mean final dose was: 30.5 ± 8.7 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21663422','lexi-content-ref-23510444','lexi-content-ref-26459650','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21663422','lexi-content-ref-23510444','lexi-content-ref-26459650','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Maintenance therapy</i>: Oral: Titrate dose to 600 to 1,200 mg/day in divided doses and target serum trough concentration of 0.8 to 1 mEq/L as tolerated.</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight ≥30 kg: Oral: Initial: 300 mg 3 times daily, increase dose in 300 mg/day increments every 3 days as tolerated to clinical response and goals based on type of therapy (acute or maintenance).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Acute therapy:</i> Oral: Titrate dose to 600 mg twice or 3 times daily and target serum lithium concentration of 0.8 to 1.2 mEq/L; a maximum dose is not described in the manufacturer labeling; in trials, reported doses did not exceed a maximum daily dose of 40 mg/kg/<b>day</b> and doses were not further increased if serum lithium concentration was ≥1.4 mEq/L. In a multicenter, double-blind, placebo-controlled efficacy trial for treatment of acute mania, the mean effective daily dose was 1,583 ± 524 mg/<b>day</b>. For all patients in the trial (regardless of weight) the mean final dose was 30.5 ± 8.7 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21663422','lexi-content-ref-23510444','lexi-content-ref-26459650','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21663422','lexi-content-ref-23510444','lexi-content-ref-26459650','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Maintenance therapy</i>: Oral: Titrate dose to 300 to 600 mg twice or 3 times daily and target serum trough concentration of 0.8 to 1 mEq/L as tolerated; in a long-term trial, doses were not further increased if serum lithium concentration was ≥1.4 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23510444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23510444'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Lithium citrate oral solution:</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight &lt;30 kg: Oral: Initial: 8 mEq twice daily, increase dose at weekly intervals in 8 mEq increments as tolerated to clinical response and goals based on type of therapy (acute or maintenance).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Acute therapy</i>: Titrate dose to 16 to 40 mEq/day in divided doses and target serum lithium concentration of 0.8 to 1.2 mEq/L; a maximum dose is not described in the manufacturer labeling; in trials, weight-dependent maximum daily doses were reported: Patients &lt;23 kg: 900 mg of lithium carbonate/<b>day</b>; patients ≥23 kg: 40 mg of lithium carbonate/kg/<b>day</b> and doses were not further increased if serum lithium concentration was ≥1.4 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21663422','lexi-content-ref-23510444','lexi-content-ref-26459650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21663422','lexi-content-ref-23510444','lexi-content-ref-26459650'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Maintenance therapy</i>: Oral: Titrate dose to 16 to 32 mEq/day in divided doses and target serum trough concentration of 0.8 to 1 mEq/L as tolerated and doses were not further increased if serum lithium concentration was ≥1.4 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21663422','lexi-content-ref-23510444','lexi-content-ref-26459650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21663422','lexi-content-ref-23510444','lexi-content-ref-26459650'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight ≥30 kg: Oral: Initial: 8 mEq 3 times daily, increase dose in 8 mEq increments every 3 days as tolerated to clinical response and goals based on type of therapy (acute or maintenance).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Acute therapy</i>: Oral: Titrate dose to 16 mEq twice or 3 times daily and target serum lithium concentration of 0.8 to 1.2 mEq/L; maximum doses are not described in the manufacturer labeling; in trials, reported doses did not exceed a maximum daily dose of: 40 mg of lithium carbonate/kg/<b>day</b> and doses were not further increased if serum lithium concentration was ≥1.4 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21663422','lexi-content-ref-23510444','lexi-content-ref-26459650','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21663422','lexi-content-ref-23510444','lexi-content-ref-26459650','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Maintenance therapy</i>: Oral: Titrate dose to 8 to 16 mEq twice or 3 times daily and target serum trough concentration of 0.8 to 1 mEq/L as tolerated; in a long-term trial, doses were not further increased if serum lithium concentration was ≥1.4 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23510444']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23510444'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release:</i> Children ≥12 years and Adolescents: Oral: Weight-based usual daily dosing administered in 2 divided doses: &lt;22 kg: 600 mg/day; 22 to 41 kg: 900 mg/day, and &gt;41 kg: 1,200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.2016'])">Ref</a></span>). In an open-label trial of 27 subjects (age range: 12 to 18 years), an initial dose of 15 mg/kg/dose twice daily, maximum initial dose: 600 mg/dose, with dose titration at weekly intervals as tolerated to target serum lithium concentration of 1 to 1.2 mEq/L was used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16540813','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16540813','lexi-content-ref-manu.1'])">Ref</a></span>). In adults, therapy is initiated at a low dose (eg, 450 mg 2 times daily or less); increased gradually based on response and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11958165']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11958165'])">Ref</a></span>); the usual adult dosage is 900 to 1,800 mg/day in 2 divided doses.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51128471"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Immediate release: Children ≥7 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &gt;89 mL/minute: No dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 30 to 89 mL/minute: Initiate therapy with low dose; titrate slowly with frequent monitoring.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute: Avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">Extended release: Children ≥12 years and Adolescents: Oral: There are no dosage adjustments provided in the manufacturer's labeling; monitor renal function closely during therapy and re-evaluate treatment with any changes in renal function.</p></div>
<div class="block dohp drugH1Div" id="F51128472"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F55690558"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cardiac effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lithium may cause <b>cardiac arrhythmia</b>, including <b>bradycardia</b>, sinoatrial dysfunction (SA block), <b>abnormal T waves on ECG</b> (T-wave inversion), and ST-segment depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29247520','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29247520','lexi-content-ref-24991789'])">Ref</a></span>). Additional cardiovascular affects have occurred, including peripheral <b>edema</b>, <b>hypotension</b>, and cardiovascular collapse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29247520','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29247520','lexi-content-ref-24991789'])">Ref</a></span>). Brugada syndrome (Brugada ECG pattern) may be unmasked with lithium therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32850223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32850223'])">Ref</a></span>). In a scientific statement from the American Heart Association, lithium has been determined to be an agent that may cause direct myocardial toxicity that is reversible upon discontinuation (magnitude: major) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27400984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27400984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Serum concentration-related; affects various ion channels in the myocardium, in particular Na/K channels, and leads to decreased intracellular potassium levels. These changes alter the normal functioning of the myocardium, leading to conduction disturbances and ECG abnormalities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29247520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29247520'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may occur within days of initiation of medication, dose increase, or addition of interacting medication or be delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29247520']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29247520'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher serum levels, particularly toxic levels (&gt;1.5 mEq/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29247520','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29247520','lexi-content-ref-24991789'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent medications that either inhibit the excretion of lithium via the kidneys or have additive effects on the myocardium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29247520','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29247520','lexi-content-ref-24991789'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29247520','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29247520','lexi-content-ref-24991789'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Brugada syndrome: Family history of Brugada syndrome, family history of sudden death at a young age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32850223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32850223'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lithium may cause a variety of CNS effects in adult and pediatric patients including <b>drowsiness</b>, <b>sedated state</b>, <b>ataxia</b>, <b>abnormal gait</b>, <b>confusion</b>, decreased alertness, <b>disorientation</b>, <b>lethargy, memory impairment</b>, <b>slurred speech</b>, <b>headache</b>, and others (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21663422','lexi-content-ref-26459650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21663422','lexi-content-ref-26459650'])">Ref</a></span>) . More significant manifestations may occur with elevated serum lithium levels or toxicity, such as <b>coma</b>, <b>seizure </b>(including tonic-clonic twitching), <b>hallucination</b>, agitation, <b>abnormal electroencephalogram</b> (EEG), and may proceed to death without intervention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>). Of note, some patients may describe decreased creativity and cognitive dulling as an adverse reaction, when it could also be a result of effective treatment of their manic episode and resultant decreased manic symptoms. CNS effects may persist indefinitely during treatment. Tolerance may or may not occur over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>). Cognitive adverse reactions may be a reason for medication nonadherence, but it is unclear whether these adverse reactions are associated with lithium or bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32457664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32457664'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; may be related to neuronal cell membrane polarization/depolarization, alterations in glutamate functioning, increases in serotonin release, inhibition of inositol monophosphatase, and alteration of CNS catecholamine levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24991789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; may begin soon after initiation. Effects may be exacerbated with dose increases (or increased serum levels) or intentional or unintentional overdoses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses/serum levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications reducing the clearance of lithium (eg, angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs, diuretics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32457664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32457664'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other CNS depressant medications (eg, sedative-hypnotics, antipsychotics, antiseizure medications, etc.) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32457664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32457664'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting neurocognitive impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32457664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32457664'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Current episode of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dermatologic effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lithium may cause <b>acne vulgaris</b> and/or <b>psoriasis</b> (including <b>exacerbation of acne</b> and <b>exacerbation of psoriasis</b>) in patients with and without either condition at baseline. May vary from mild to severe, and occur on the face, scalp, trunk, and extremities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-28274352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-28274352'])">Ref</a></span>). Plaque-type psoriasis is the most common presentation, but others may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19287551']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19287551'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; may exert toxic effects on the follicular epithelium, producing acne through neutrophilic chemotaxis and degranulation. In addition, the inflammatory cascade may become activated, leading to psoriasis. Follicular plugging may also contribute to these effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28274352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28274352'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically takes several months to develop, although exacerbations of existing acne or psoriasis may occur sooner (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28274352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28274352'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-28274352']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-28274352'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting moderate to severe psoriasis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">GI effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A variety of adverse GI effects have been reported with lithium in adult and pediatric patients, including <b>dyspepsia</b>, <b>diarrhea</b>,<b> nausea</b>, <b>vomiting</b>, <b>dysgeusia</b> (metallic or salty taste), <b>gastritis</b>, and <b>abdominal pain</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21663422','lexi-content-ref-26459650']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21663422','lexi-content-ref-26459650'])">Ref</a></span>). Some effects (eg, nausea) my subside over time. Vomiting is typically associated with toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>). Supratherapeutic lithium concentrations should be suspected with severe nausea, vomiting, and diarrhea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24991789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; may be related to direct irritation on the stomach lining or related to other physiological processes in the body after absorption. Potential effects of increased serotonin release may play a role in nausea, as well as general electrolyte changes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-24991789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; some effects (eg, nausea, diarrhea) may occur early in treatment. Other effects may take longer to develop (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Earlier in treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses/serum levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Peak lithium levels (possible association) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Controlled-release preparations may be associated with less upper GI cramping and nausea, but increased diarrhea compared to immediate-release formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27770296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27770296'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperparathyroidism and hypercalcemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypercalcemia</b> has been reported with lithium treatment, which may or may not be related to drug-induced <b>hyperparathyroidism</b>. Symptoms may include weakness, fatigue, development of renal stones (calculi), osteoporosis, GI distress, and others. Psychiatric disturbances, including depression, may also develop, and potentially be misinterpreted as a new episode of the underlying mood disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-25853371','lexi-content-ref-19252941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-25853371','lexi-content-ref-19252941'])">Ref</a></span>). Changes are usually reversible if lithium is discontinued; however, sustained hypercalcemia and parathyroid gland enlargement have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22985484']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22985484'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: While unclear, lithium is thought to inhibit calcium receptors in the parathyroid gland, preventing inhibition of parathyroid hormone (PTH) release. As PTH levels rise, this alters calcium homeostasis leading to hypercalcemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25853371','lexi-content-ref-19252941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25853371','lexi-content-ref-19252941'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; while lithium has been observed to affect PTH levels after a single dose, more long-term exposure (ie, years) is likely required to observe clinically relevant alterations in calcium homeostasis. Progression to osteoporosis would likely take a significant exposure time as well (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19252941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19252941'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Exact risk factors unclear, but may include:</p>
<p style="text-indent:-2em;margin-left:8em;">• Longer duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25853371','lexi-content-ref-19252941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25853371','lexi-content-ref-19252941'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25853371','lexi-content-ref-19252941']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25853371','lexi-content-ref-19252941'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypothyroidism</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lithium treatment has been associated with various thyroid function abnormalities, but most commonly <b>hypothyroidism</b> in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26459650','lexi-content-ref-14726729']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26459650','lexi-content-ref-14726729'])">Ref</a></span>). Patients may present with typical hypothyroidism signs and symptoms, including lethargy, impaired cognition, weight gain, dry skin, and cold intolerance. Additionally, depressive symptoms may worsen/emerge and be misinterpreted as a component of the underlying mood disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-31670617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-31670617'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: While unclear, it is thought that lithium has varied effects on thyroid hormone production and regulation, including inhibition of iodine uptake in the thyroid, inhibition of thyroid hormone synthesis and release, and hepatic conversion of free thyroxine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23391071']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23391071'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Hypothyroid features, either symptomatic or lab-value based, generally occur after years of lithium treatment. While acute changes have been noted within the first month of treatment, it is much more likely after several years of use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31670617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31670617'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of hypothyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of antithyroid antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Lithium toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lithium is classified as a narrow-therapeutic index drug, requiring close monitoring to ensure patients’ serum levels are maintained within the therapeutic range. Supratherapeutic levels, even slight elevations above 1.5 mEq/L, may lead to increased adverse reactions and toxicity. Notably, toxicity can occur at any level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28576914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28576914'])">Ref</a></span>). General symptoms of low-grade lithium toxicity may include weakness, <b>tremor </b>(new-onset or worsening), mild <b>ataxia</b>, poor concentration, <b>tinnitus</b>, <b>nausea</b>, and <b>diarrhea</b>. More significant toxicity may result in <b>vomiting</b>, gross/coarse tremor, <b>slurred speech</b>, <b>confusion</b>, <b>nystagmus disorder</b>, dysarthria, and lethargy. If not treated, it may lead to <b>seizure</b> (tonic-clonic), <b>coma</b>, neurological damage, and death (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-24991789'])">Ref</a></span>). Permanent neurotoxicity, described as the syndrome of irreversible lithium-effectuated neurotoxicity (SILENT), has been reported with acute and chronic lithium toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15714160']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15714160'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Lithium toxicity is an augmented presentation of the various adverse reactions seen with treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-24991789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may occur within minutes of ingestion (mostly GI effects), but more significant symptoms may take over an hour or more to manifest. There are also reports of delayed symptom onset several days after ingestion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-24991789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses/serum levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-24991789'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of drugs or medications (eg, nonsteroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists) that increase serum levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-24991789'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Acute alterations in serum electrolytes or dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-24991789'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (may manifest symptoms at lower comparative serum levels) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-24991789'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-24991789'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Nephrogenic diabetes insipidus</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrogenic diabetes insipidus</b> may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31007893','lexi-content-ref-31837914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31007893','lexi-content-ref-31837914'])">Ref</a></span>). The ability of the kidney to retain free water may become impaired, leading to dehydration and electrolyte disturbances, most notably hypernatremia. Additionally, serum lithium levels may increase due to the decreased dilutional effect from decreased whole body water. Symptoms of nephrogenic diabetes insipidus and its related hypernatremia may include polyuria, polydipsia, lethargy, and irritability. More severe cases may progress to muscle twitching, coma, seizures, and death. Nephrogenic diabetes insipidus may persist after prolonged lithium therapy despite discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30390660','lexi-content-ref-31007893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30390660','lexi-content-ref-31007893'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and duration-related. Lithium-related changes in the collecting tubules of the kidney decrease sensitivity to antidiuretic hormone, leading to decreased concentrating ability and increased production of dilute urine. Lithium may reduce aquaporin-2 water channels within the collecting duct, causing reduction of water reabsorption (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31837914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31837914'])">Ref</a></span>). As total body stores of free water decrease, the sensation of thirst increases to compensate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30390660','lexi-content-ref-27900734','lexi-content-ref-31007893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30390660','lexi-content-ref-27900734','lexi-content-ref-31007893'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typical onset within 2 to 4 months of initiation but may occur earlier or later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30390660','lexi-content-ref-31007893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30390660','lexi-content-ref-31007893'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30390660','lexi-content-ref-31007893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30390660','lexi-content-ref-31007893'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses/serum levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30390660','lexi-content-ref-31007893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30390660','lexi-content-ref-31007893'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Any episodes of lithium toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30390660','lexi-content-ref-31007893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30390660','lexi-content-ref-31007893'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Extended release or multiple-daily dose regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30390660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30390660'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Nonresponse to lithium (may be a risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30390660']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30390660'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31007893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31007893'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dehydration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31007893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31007893'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Alcohol intoxication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31007893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31007893'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Polydipsia and polyuria</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Common adverse reactions associated with lithium are <b>polyuria</b> and <b>polydipsia</b>. These reactions may vary in intensity from mild to more significant effects on overall quality of life. Patients may notice increased urinary frequency (&gt;3 L in 24 hours) due to poor urine concentration. As a result of decreased body water stores, patients may also report increased thirst, which is independent of any dry mouth effects of the drug. May decrease in intensity over time in some patients as the kidneys compensate for this effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>). Refer to "nephrogenic diabetes insipidus" for long-term complications.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Lithium-related changes in the collecting tubules of the kidney decrease sensitivity to antidiuretic hormone, leading to decreased concentrating ability and increased production of dilute urine. As total body stores of free water are decreased, the sensation of thirst increases to compensate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may occur early in treatment (within days) or later in treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses/serum levels episodes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Any episodes of lithium toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other psychotropic medications, especially antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Multiple-daily dose regimens (conflicting data) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Renal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Up to one-third of patients may develop some degree of decreased kidney function over the course of lithium treatment, with a smaller percentage (~5%) developing significant kidney impairment/failure (eGFR &lt;30 mL/minute). Changes in eGFR (<b>decreased creatinine clearance</b>), <b>renal concentrating defect</b>, and other parameters have been observed in these patients. The development of polyuria/polydipsia may or may not be an early marker for later development of kidney insufficiency. Progression of kidney impairment may continue after discontinuation of lithium in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-29346806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-29346806'])">Ref</a></span>). Chronic kidney disease will develop in 17% to 21% of long-term users (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31837914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31837914'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Duration-related; related to various changes in kidney morphology, including <b>interstitial nephritis </b>and fibrosis, <b>nephron atrophy</b>, and possibly glomerular damage. Hypothesized to be related to acute decreases in kidney sensitivity to antidiuretic hormone, causing gradual change in kidney function over time (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-29346806','lexi-content-ref-31837914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-29346806','lexi-content-ref-31837914'])">Ref</a></span>). Time from lithium initiation to progression to chronic kidney disease and end stage renal disease is 16.5 to 31 years, and 23 years, respectively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31837914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31837914'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Typically delayed, although acute changes may occur with acute toxicity. As lithium exposure continues over years, the rate of more significant kidney impairment increases as the alternations in kidney structure become more severe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-29346806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-29346806'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer duration of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-31837914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-31837914'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Any episodes of lithium toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses/serum concentrations (probable risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31837914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31837914'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other psychotropic medications, especially antipsychotics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-31837914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-31837914'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Various types of sexual dysfunction have been reported with lithium treatment, in both females and males. While the rates of the various effects are not clear (anywhere from &lt;5% to nearly 40% in studies), they may include decreased libido, impaired sexual arousal, erectile dysfunction, and general decreased sexual satisfaction. Negative effects on orgasm are unclear. Sexual dysfunction can negatively impact patients’ quality of life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32139195','lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32139195','lexi-content-ref-27900734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism is unclear. Effects on promoting serotonin release may play a role, similar to the serotonin-augmenting effects of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24991789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may take days to weeks or longer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32139195','lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32139195','lexi-content-ref-27900734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">No clear risk factors have been described. Possible risk factors include:</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent use of benzodiazepines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32139195','lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32139195','lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent use of other medications that cause sexual dysfunction (eg, antidepressants) (probable risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32139195','lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32139195','lexi-content-ref-27900734'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Tremor</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Lithium may cause <b>tremor</b> in nearly one-quarter of patients, making it one of the most common adverse reactions. Most commonly seen as a bilateral, symmetrical hand tremor, similar to essential tremor; although, this may vary to other limbs and in symmetry (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734','lexi-content-ref-24991789','lexi-content-ref-31837914']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734','lexi-content-ref-24991789','lexi-content-ref-31837914'])">Ref</a></span>). May spontaneously decrease over time as compensatory mechanisms develop within the patient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>). Course tremor and muscle twitching may be observed in lithium toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24991789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism is unclear; thought to be related to CNS depressant effects, leading to dysregulation of fine muscle control (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24991789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24991789'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; commonly begins early in treatment but can develop later in treatment (with or without a dose increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses/serum levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications reducing the clearance of lithium (eg, angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonists, nonsteroidal anti-inflammatory drugs, diuretics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other medications known to induce tremor (eg, antipsychotics, antidepressants) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of caffeine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent anxiety disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Personal or family history of essential tremor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent substance withdrawal (especially alcohol) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Weight gain</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight gain</b> is reported as one of the more common and bothersome adverse reactions of lithium. May include weight gain of 10 kg or more over time with an average increase in body weight of 6 kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>). This can lead to other medical comorbidities and negative effects on mood and adherence to treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>). Many pediatric studies suggest that lithium has a low risk for weight gain (not statistically different than placebo), with many demonstrating that it is weight neutral (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31242784']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31242784'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism is unclear. Effects on central mechanisms related to weight gain, satiety, and metabolism are possible. In addition, increased consumption of high-calorie, sugary beverages from increased thirst due to lithium could play a role, as well as any drug-induced hypothyroidism and fluid retention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; may occur within the first few weeks of initiation, with more significant increases over time. Increases of 4 to 7 kg within the first year have been reported in the literature. While the most significant weight gain typically occurs within the first 1 to 2 years of treatment, it may continue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Unclear, but may include:</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent use of other medications that can cause weight gain (particularly other psychotropic medications) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Early weight gain after treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27900734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27900734'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Overweight/obese prior to initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32457664']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32457664'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F189309"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Abnormal T waves on ECG (including inversion T wave on ECG and flattened T wave of ECG), bradycardia (Ataallah 2020), cardiac arrhythmia (including unmasking of Brugada Syndrome) (Ravi 2020), chest tightness, circulatory shock, cold extremities, edema, hypotension, myxedema (Ahmad Mir 2013), peripheral vascular disease (resembling Raynaud’s syndrome), prolonged QT interval on ECG, sinus node dysfunction, syncope, ventricular tachyarrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (Scarfi 2013), alopecia, dermal ulcer, dermatitis, dry and/or thinning hair, exacerbation of acne (Gitlin 2016), exacerbation of psoriasis, folliculitis, pruritus, psoriasis, skin rash, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, dehydration, diabetes insipidus, euthyroid goiter, glycosuria, hypercalcemia (including secondary to hyperparathyroidism [McKnight 2012]), hyperglycemia, hypermagnesemia, hyperparathyroidism, hyperthyroidism, hyponatremia, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, decreased appetite, dental caries, dysgeusia (including metallic taste and salty taste), dyspepsia, fecal incontinence, flatulence, gastritis, salivary gland disease (swelling), sialorrhea, swelling of lips, tongue changes (movement), vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Glomerulopathy (fibrosis), impotence, nephron atrophy, nephrotic syndrome (Bear 1985), oliguria, sexual disorder, urinary incontinence</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukocytosis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Drug reaction with eosinophilia and systemic symptoms (Shreedhar 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Local pain (fingers and toes), local skin discoloration (fingers and toes), localized edema (ankles and wrists)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal electroencephalogram (diffuse slowing, potentiation, disorganization of background rhythm), abnormal gait, ataxia, bradyphrenia, cogwheel rigidity, coma, confusion, decreased mental acuity (worsening of organic brain syndromes), disorientation, dizziness, drowsiness, dystonic reaction, epileptiform seizure, extrapyramidal reaction, fatigue, hallucination, headache, hyperactive behavior (startled response), hyperactive deep tendon reflex, hyperirritability (muscle), hypertonia, idiopathic intracranial hypertension, involuntary choreoathetoid movements, lethargy, local anesthesia (skin), memory impairment, myasthenia, psychomotor impairment, restlessness, sedated state, seizure, slurred speech, stupor, tic disorder, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, joint swelling, polyarthralgia, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, exophthalmos, nystagmus disorder, transient scotoma</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Decreased creatinine clearance, interstitial nephritis, renal concentrating defect</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, interstitial fibrosis, iodism (elevated iodine uptake)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypothyroidism (common: ≥10%) (Lieber 2020), nephrogenic diabetes insipidus (common: ≥10%) (Ott 2019, Rauf 2020, Schoot 2020), polydipsia (common in long-term patients: ≥10%) (Gitlin 2016), weight gain (common: ≥10%) (Gitlin 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (common: ≥10%) (Gitlin 2016), nausea (common: ≥10%) (Gitlin 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Intracranial hypertension (Tan 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lupus-like syndrome (Shukla 1982)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Polyuria (common in long-term patients: ≥10%) (Gitlin 2016)</p></div>
<div class="block coi drugH1Div" id="F189324"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to lithium or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Immediate-release capsule, solution and tablet: Severe cardiovascular or renal disease, severe debilitation, dehydration, sodium depletion, concurrent use with diuretics.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US manufacturer’s labeling): Brain damage; conditions requiring low sodium intake.</p></div>
<div class="block war drugH1Div" id="F189306"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pseudotumor cerebri: Pseudotumor cerebri (increased intracranial pressure and papilledema) has rarely been reported with use; undetected cases may result in blind spot enlargement, visual field constriction, and blindness secondary to optic atrophy. Discontinue therapy, if clinically possible, if syndrome occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serotonin syndrome: Lithium can precipitate a potentially life-threatening serotonin syndrome, particularly when used in combination with other serotonergic agents (eg, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, triptans, tricyclic antidepressants, fentanyl, tramadol, buspirone, St. John's wort, tryptophan) or agents that impair metabolism of serotonin (eg, monoamine oxidase inhibitors). Monitor patients closely for signs of serotonin syndrome, such as mental status changes (eg, agitation, hallucinations, delirium, coma), autonomic instability (eg, tachycardia, labile BP, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular changes (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination), GI symptoms (eg, nausea, vomiting, diarrhea), and/or seizures. Discontinue treatment (and any concomitant serotonergic agent) immediately if signs/symptoms arise and initiate supportive therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Generally avoid use in patients with significant cardiovascular disease due to risk of precipitation of cardiac arrhythmia; if use is unavoidable, use with extreme caution and monitor serum lithium levels and EKG closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Depression/suicidal ideation: Use with caution in patients at risk of suicide (suicidal thoughts or behavior) by drug overdose; lithium has a narrow therapeutic index (Nelson 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use with caution in patients with myasthenia gravis; may exacerbate condition (Mehrizi 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p></div>
<div class="block prod-avail drugH1Div" id="F56582557"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Lithium oral solution has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F189316"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as carbonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 300 mg, 600 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as citrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 8 mEq/5 mL (500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as carbonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral, as carbonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lithobid: 300 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 300 mg, 450 mg</p></div>
<div class="block geq drugH1Div" id="F189302"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F189326"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Lithium Carbonate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.14 - $0.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $0.17 - $1.71</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">600 mg (per each): $0.39 - $1.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lithium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mEq/5 mL (per mL): $0.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Lithium Carbonate ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $0.25 - $0.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">450 mg (per each): $0.46 - $0.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Lithobid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $15.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lithium Carbonate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $0.21 - $0.34</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867386"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as carbonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carbolith: 150 mg, 300 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Carbolith: 600 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lithane: 150 mg, 300 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 300 mg, 600 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral, as carbonate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lithmax: 300 mg</p></div>
<div class="block adm drugH1Div" id="F189321"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with meals to decrease GI upset. ER tablets must be swallowed whole; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Even though some ER lithium tablets have markings that look like score marks, the manufacturer's labeling recommends that ER tablets be taken whole and not cut, chewed, or crushed. Options include to switch to IR capsule or tablet; be aware that the peak serum concentration is reached much faster than the extended release and if capsules are opened or tablets crushed, this could be reached even faster and patient may experience stomach upset or nausea. Alternatively, switch to oral solution but be aware of appropriate dose conversion since the liquid form is a different lithium salt. Of note, lithium clearance is impacted by body weight, so as patient loses weight after bariatric surgery, dose adjustments may be necessary. Therapeutic drug monitoring recommended.</p></div>
<div class="block admp drugH1Div" id="F52613169"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with meals to decrease GI upset. Do not crush or chew extended release dosage form; swallow whole.</p></div>
<div class="block meg drugH1Div" id="F54124342"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Lithium: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F017812s036%2C018421s035%2C018558s030lbl.pdf%23page%3D19&amp;token=dTSqj%2BkycvIML9qGCojjEBzttV9DpKC0AEdOhCHLaSw6uWjeNIEKpnuIRw6SoL0VRDfiSyBs3sEmYHUmn9L71JW9VZsfWB%2BGBuq5AeL48GsCXA2FhEY1KAS6d8JnhU0%2BXja%2F3wJWppPyuvPhDH3%2B7A%3D%3D&amp;TOPIC_ID=9566" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/017812s036,018421s035,018558s030lbl.pdf#page=19</a></p></div>
<div class="block use drugH1Div" id="F189320"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immediate release: </i>Treatment of acute mania, acute episodes with mixed features, and maintenance treatment in patients ≥7 years of age with a diagnosis of bipolar disorder.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release: </i>Treatment of manic episodes and maintenance treatment in patients ≥12 years of age with a diagnosis of bipolar disorder.</p></div>
<div class="block off-label drugH1Div" id="F25726821"><span class="drugH1">Use: Off-Label: Adult</span><p>Bipolar disorder, hypomania; Bipolar major depression; Major depressive disorder, unipolar</p></div>
<div class="block mst drugH1Div" id="F189394"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Eskalith may be confused with Estratest.</p>
<p style="text-indent:0em;margin-left:2em;">Lithium may be confused with lanthanum, Ultram.</p>
<p style="text-indent:0em;margin-left:2em;">Lithobid may be confused with Levbid, Lithostat.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Do not confuse <b>mEq</b> (milliequivalent) with <b>mg</b> (milligram). <b>Note:</b> 300 mg lithium carbonate or citrate contain 8 mEq lithium. Dosage should be written in <b>mg</b> (milligrams) to avoid confusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Check prescriptions for unusually high volumes of the syrup for dosing errors.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299613"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F189311"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II Receptor Blockers: May increase the serum concentration of Lithium. Management: Initiate lithium at lower doses in patients receiving an angiotensin II receptor blocker (ARB). Consider lithium dose reductions in patients stable on lithium therapy who are initiating an ARB. Monitor lithium concentrations closely when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: May increase the serum concentration of Lithium. Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor for increased concentrations/toxic effects of lithium if an ACE inhibitor is initiated/dose increased, or if switching between ACE inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Lithium may enhance the neurotoxic effect of Antipsychotic Agents. Lithium may decrease the serum concentration of Antipsychotic Agents. Specifically noted with chlorpromazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: May decrease the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcitonin: May decrease the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers (Nondihydropyridine): May enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered lithium concentrations have also been reported with this combination.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Polystyrene Sulfonate: May decrease the serum concentration of Lithium. Management: Consider separating administration of lithium from administration of oral calcium polystyrene sulfonate by at least 6 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May enhance the adverse/toxic effect of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May decrease the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Lithium may diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May enhance the adverse/toxic effect of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Lithium. This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May decrease the serum concentration of Lithium. Loop Diuretics may increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methyldopa: May enhance the adverse/toxic effect of Lithium. This may occur without notable changes in serum lithium concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: May enhance the serotonergic effect of Lithium. This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Lithium. MetroNIDAZOLE (Systemic) may increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): May enhance the serotonergic effect of Lithium. This could result in serotonin syndrome. Management: Consider alternatives to this drug combination. If combined, monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Type B): May enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Lithium may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Lithium. Management: Consider reducing the lithium dose when initiating a NSAID. Monitor for increased lithium therapeutic/toxic effects if a NSAID is initiated/dose increased, or decreased effects if a NSAID is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4 and CYP2D6): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Lithium. Ornidazole may increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osmotic Diuretics: May decrease the serum concentration of Lithium. Management: Consider temporarily discontinuing use of osmotic diuretics during coadministration with lithium. If coadministration is required, monitor lithium concentrations and for signs of lithium toxicity frequently.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Iodate: Lithium may enhance the hypothyroid effect of Potassium Iodate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Iodide: May enhance the hypothyroid effect of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: May increase the serum concentration of Lithium. Potassium-Sparing Diuretics may decrease the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sargramostim: May enhance the adverse/toxic effect of Lithium. Specifically, the myeloproliferative effects may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: Serotonergic Agents (High Risk, Miscellaneous) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: Serotonergic Agents (High Risk, Miscellaneous) may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): May enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: Lithium may enhance the QTc-prolonging effect of Sertindole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Chloride: May increase the excretion of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Polystyrene Sulfonate: May decrease the serum concentration of Lithium. Management: Consider separating administration of lithium from administration of oral sodium polystyrene sulfonate by at least 6 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May decrease the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: May decrease the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May decrease the excretion of Lithium. Management: Reduce the lithium dose if coadministered with thiazide or thiazide-like diuretics. Monitor serum lithium levels during coadministration with thiazide and thiazide-like diuretics.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the serotonergic effect of Serotonergic Agents (High Risk, Miscellaneous). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tryptophan: Lithium may enhance the serotonergic effect of Tryptophan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Lithium may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing Diabetes Insipidus may diminish the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic hormone effects of vasopressin may be decreased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F189327"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Lithium crosses the placenta in concentrations similar to those in the maternal plasma (Newport 2005).</p>
<p style="text-indent:0em;margin-top:2em;">Cardiac malformations in the infant, including Ebstein anomaly, are associated with use of lithium during the first trimester of pregnancy. Other adverse events including polyhydramnios, fetal/neonatal cardiac arrhythmias, hypoglycemia, diabetes insipidus, changes in thyroid function, premature delivery, floppy infant syndrome, or neonatal lithium toxicity are associated with lithium exposure when used later in pregnancy (ACOG 2008). The incidence of adverse events may be associated with higher maternal doses (Newport 2005). Fetal echocardiography should be considered if first trimester exposure occurs (ACOG 2008).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, women who are pregnant may require dose adjustments of lithium to achieve euthymia and avoid toxicity (ACOG 2008; Grandjean 2009; Yonkers 2011).</p>
<p style="text-indent:0em;margin-top:2em;">For planned pregnancies, use of lithium during the first trimester should be avoided if possible (Grandjean 2009). However, the absolute risk of Ebstein anomaly is small and treatment for bipolar disorder should not be withheld when clinically indicated (Larsen 2015). If lithium is needed during pregnancy, the minimum effective dose should be used, maternal serum concentrations should be monitored, and consideration should be given to start therapy after the period of organogenesis; lithium should be suspended 24 to 48 hours prior to delivery or at the onset of labor when delivery is spontaneous, then restarted when the patient is medically stable after delivery (ACOG 2008; Grandjean 2009; Newport 2005).</p></div>
<div class="block brc drugH1Div" id="F16343841"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Lithium is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Serum concentrations of breastfeeding infants may be 10% to 50% of the maternal serum concentration (Grandjean 2009). Hypotonia, hypothermia, cyanosis, electrocardiogram changes, and lethargy have been reported in breastfed infants (ACOG 2008). It is generally recommended that breastfeeding be avoided during maternal use of lithium; however, treatment may be continued in appropriately selected patients (Grandjean 2009; Larsen 2015; Sharma 2009; Viguera 2007). The hydration status of the breastfed infant and maternal serum concentrations of lithium should be monitored (ACOG 2008). In addition, monitor the infant for lethargy, growth, and feeding problems; obtain infant serum concentrations only if clinical concerns arise (Bogen 2012; Yonkers 2011). Long-term effects on development and behavior have not been studied (ACOG 2008; Grandjean 2009).</p></div>
<div class="block dic drugH1Div" id="F189328"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken with meals to avoid GI upset; maintain adequate salt and fluid intake.</p></div>
<div class="block mop drugH1Div" id="F189314"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function including BUN and SCr (baseline, every 2 to 3 months during the first 6 months of treatment, then once a year in stable patients or as clinically indicated); fluid status; pediatric patients may require more frequent checks); serum electrolytes (baseline, then periodically), serum calcium (baseline, 2 to 6 weeks after initiation, then every 6 to 12 months; repeat as clinically indicated; if discontinued due to hypercalcemia, monitor weekly for 1 month for return to baseline) (Broome 2011); signs and symptoms of hypercalcemia (eg, fatigue, weakness, abdominal pain, constipation, nephrolithiasis, bone pain); thyroid (baseline, 1 to 2 times with in the first 6 months of treatment, then once a year in stable patients or as clinically indicated); PTH as clinically indicated; beta-hCG pregnancy test for all females not known to be sterile (baseline); ECG with rhythm strip (baseline for all patients &gt;40 years of age or if underlying cardiac risk factors, repeat as clinical indicated), CBC with differential (baseline, repeat as clinically indicated) (APA 2002; Mehta 2017); serum lithium levels once weekly until both patient's clinical status and levels are stable, then repeat levels every 3 to 6 months or as clinically indicated [APA 2002; NICE 2022]; closely monitor in patients with significant renal or cardiovascular disease, debilitation, dehydration, sodium depletion, or those taking concomitant medications that impact renal function); weight (baseline, then periodically) (APA 2002; Mehta 2017); polyuria; signs of lithium toxicity (eg, diarrhea, vomiting, tremor, mild ataxia, drowsiness, muscular weakness).</p></div>
<div class="block rer drugH1Div" id="F189317"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Monitor symptom improvement in conjunction with serum concentrations to guide dose adjustments. Obtain 2 consecutive serum concentrations in the therapeutic range during the acute phase, then monitor regularly (ie, every 3 to 6 months).</p>
<p style="text-indent:-2em;margin-left:2em;">Timing of serum samples: A 12-hour trough level is preferred, but in some circumstances (eg, 3 times a day dosing, limited lab hours) it may be drawn 8 to 12 hours post dose. Check levels ~5 days after a dosage adjustment (CANMAT [Yatham 2018]; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic concentrations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bipolar disorder:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Acute mania: 0.8 to 1.2 mEq/L (SI: 0.8 to 1.2 mmol/L); some guidelines recommend lower target serum concentrations (eg, 0.4 to 0.8 mEq//L [SI: 0.4 to 0.8 mmol/L]) for older adults.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance: 0.6 to 1 mEq/L (SI: 0.6 to 1.0 mmol/L); a higher rate of relapse is described in subjects who are maintained at &lt;0.6 mEq/L (SI: 0.6 mmol/L). Some guidelines recommend targeting the lower end of the range for older adults (CANMAT [Yatham 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Major depressive disorder: </i>0.6 to 0.9 mEq/L (SI: 0.6 to 0.9 mmol/L) (NICE 2022; VA/DoD 2022). In patients &gt;65 years, consider targeting lowering levels (eg, 0.4 to 0.6 mEq/L [SI: 0.4 to 0.6 mmol/L]) (NICE 2022).</p>
<p style="text-indent:-2em;margin-left:2em;">Toxic concentrations</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;1.5 mEq/L (SI: &gt;1.5 mmol/L): Early signs and symptoms of intoxication may include marked tremor, nausea, diarrhea, blurred vision, vertigo, confusion, and decreased deep tendon reflexes (APA 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;2.5 mEq/L (SI: &gt;2.5 mmol/L): Intoxication symptoms may progress to include severe neurological complications, seizures, coma, cardiac dysrhythmia, and permanent neurological impairment (APA 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;3.5 mEq/L (SI: &gt;3.5 mmol/L): Potentially lethal toxicity (Mitchell 2001).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>A 10% to 26% increase of a 12-hour serum concentration can be expected with once-daily dosing compared to a 12-hour serum concentration checked of an equal dose that is given twice daily (Mitchell 2001; Singh 2011).</p></div>
<div class="block pha drugH1Div" id="F189305"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The precise mechanism of action in mood disorders is unknown. Traditionally thought to alter cation transport across cell membranes in nerve and muscle cells, influence the reuptake of serotonin and/or norepinephrine, and inhibit second messenger systems involving the phosphatidylinositol cycle (Ward 1994). May also provide neuroprotective effects by increasing glutamate clearance, inhibiting apoptotic glycogen synthase kinase activity, increasing the levels of antiapoptotic protein Bcl-2 and, enhancing the expression of neurotropic factors, including brain-derived neurotrophic factor (Sanacora 2008).</p></div>
<div class="block phk drugH1Div" id="F189323"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and complete</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: Initial: 0.307 L/kg; V<sub>dss</sub>: 0.7 to 1 L/kg; decreased in elderly patients (Ward 1994)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Not protein bound</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not metabolized (Ward 1994)</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 80% to 100% (Ward 1994)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients 7 to 17 years: t<sub>1/2(beta)</sub>: 27 hours (Findling 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 18 to 36 hours; prolonged in elderly patients (~28.5 hours) (Ward 1994)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Immediate release: ~0.5 to 3 hours; Extended release: 2 to 6 hours; Solution: 15 to 60 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (primarily; unchanged drug); sweat, saliva, and feces (negligible amounts)</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 80% of filtered lithium is reabsorbed in the proximal convoluted tubules; decreased in elderly patients secondary to age-related decreases in renal function (Ward 1994)</p></div>
<div class="block phksp drugH1Div" id="F51153972"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: In pediatric patients, great variability in clearance was found across subjects with linear pharmacokinetics correlated to fat-free mass (Findling 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Elderly patients receiving lithium may have a decreased glomerular filtration rate and decrease in renal plasma clearance (13.7 mL/minute) (Ward 1994).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F189329"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Priadel</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ceglution | Eskalit | Karlit | Lithiun</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Neurolepsin | Quilonorm</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lithicarb | Quilonum</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Lithin | Lithosun | Litiam</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Maniprex | Priadel</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Normothymin | Normothymin E | Swanson lithium orotate</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acolitium | Bilyt | Carbolim | Carbolitium | Carbonato de litio | Carbonato de litio eurofarma | Carlit | Carlit xr | Literata | Litiocar | Neurolithium</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Carbonate de Lithium Vifor | Litarex | Oligosol li | Quilonorm</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cabalex | Cade | Cadel | Carbolit | Carboron | Eskalit | Kalitium | Psicolit</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Actibutin | Actilitio | Carbolit | Carbonato de litio | Eskalit | Theralite</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Contemnol | Lithium carbonicum</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Hypnorex | Leukominerase | Li 450 ziethen | Lithiofor | Lithium | Lithium aspartat | Lithium duriles | Quilonorm | Quilonum | Quilonum retard</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Litiumkarbonat</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Carbolit | Carbonato de litio | Cymalit | Litil | Litio | Plenur</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Carbolit | Ceglution</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lithium carbonicum | Lito</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Priadel | Prianil | Prianil C.R</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Plenur</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Litarex | Lithionit | Liticar | Lito | Litoduron</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Teralithe</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Li | Li liquid | Liskonum | Litarex | Lithium carbon | Lithium citrat | Lithonate | Phasal | Phasal pharmax | Priadel</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Lithiofor | Milithin | Priadel</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo-lithium carbonate | Camcolit | Licarb | Lithiofor | Pms-lithium carbonate | Priadel</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Litij karbonat | Litijev karbonat Jadran</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Liticarb</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Frimania | Teralithe</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Priadel</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Licarbium</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Alkalith | Carbolith | Elcab | Hethium | Indlith | Intalith | Lalithium | Li | Li sr | Licab | Licar | Lisalt | Litab-sr | Litca | Litca sr | Lithic SR | Lithicab | Lithium | Lithocap | Lithocent | Litholent | Litholite | Lithorest sr | Lithoril | Lithosun | Lithotab sr | Lizen xl | Loponet | Manicarb | Monolith | Monolith sr | Procab | Salith | Staleth | Tricab</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Litarex</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Carbolithium | Litio carbonato | Litio carbonato sella | Litio carbonato zeta | Resilient</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Manicarb</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Limas | Lithium Carbonate Mitsubishi | Lithium carbonate taisho | Litiomal</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lithan | Lithion | Myungin lithium carbonate | Wi lithium carbonate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Litocip</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Contemnol | Hypnorex | Intalith cr 450 | Lithium Apogepha | Lithium carbonicum | Monolith sr | Normothymin | Normothymin E | Quilonorm | Quilonum</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Maniprex | Priadel | Quilonum</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Contemnol | Lithium carbonicum | Normothymin | Normothymin E</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Teralithe</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Carbolit | Litheum</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo-lithium carbonate</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Litarex | Lithiumcarbon | Lithiumcarbonaat | Priadel</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Apo-lithium carbonate | Hypnorex | Li | Li liquid | Litarex | Lithionit | Litio carbonato | Litiumkarbonat | Priadel</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Lithicarb | Priadel</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Carbonat de litio | Carbonato de litio | Litio carbonato | Litocarb | Prolix | Xentralin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Microlit | Quilonium r</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Lithotrope sr | Neuroglit | Neurolith | Priadel</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Lithiofor | Lithium carbonicum | Priadel</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Eskalith | Eskalith cr | Lithate | Lithobid | Lithonate | Lithotabs</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Plenur | Priadel</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Carbonato de litio dasanti | Carbonato de litio imedic | Carbonato de litio natrodale | Carbonato de litio quimfa | Carlit | Neurolitio 450 xr</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Lithium carbon gsk</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Contemnol | Lithium carbonicum | Sedalit | Sedalitum</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Camcolite | Lithiofor | Pms-lithium carbonate</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Litarex | Lithionit | Litiumkarbonat</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Camcolit</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Lithii carbonas | Litij karbonat | Quilonorm</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Contemnol | Lithium carbonicum</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Licarb | Limed | Lit | Phanate</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Lithiofor | Teralithe</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Demalit | Lithuril | Litinat</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Calith | Camcolit | Lidin | Ligilin | Lilitin | Lithcan | Lithiofor | Lithonate | Priadel</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Contemnol | Glutalit | Lithium carbonicum | Lithosun | Lithosun sr</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Eskalit | Lithane | Lithiun | Litio | Litionato Lc | Litioral | Sicolitio | Teralithe</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Carbonato de litio</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Camcolit | Lentolith | Lithium orotate assist | Quilonum</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol</i>. 2008;111:1001-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15714160">
<a name="15714160"></a>Adityanjee, Munshi KR, Thampy A. The syndrome of irreversible lithium-effectuated neurotoxicity. <i>Clin Neuropharmacol</i>. 2005;28(1):38-49. doi:10.1097/01.wnf.0000150871.52253.b7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/15714160/pubmed" id="15714160" target="_blank">15714160</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28135846">
<a name="28135846"></a>Altshuler LL, Sugar CA, McElroy SL, et al. Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double-blind comparison. <i>Am J Psychiatry</i>. 2017;174(3):266-276. doi:10.1176/appi.ajp.2016.15040558.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/28135846/pubmed" id="28135846" target="_blank">28135846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11958165">
<a name="11958165"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with bipolar disorder. <i>American Journal of Psychiatry</i>. 2002;159(4 Suppl):1-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/11958165/pubmed" id="11958165" target="_blank">11958165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2020">
<a name="APA.2020"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published October 2010. Accessed March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.2007">
<a name="Aronoff.2007"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32676239">
<a name="32676239"></a>Ataallah B, Al-Zakhari R, Sharma A, Tofano M, Haggerty G. A rare but reversible cause of lithium-induced bradycardia. <i>Cureus</i>. 2020;12(6):e8600. doi:10.7759/cureus.8600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/32676239/pubmed" id="32676239" target="_blank">32676239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17042835">
<a name="17042835"></a>Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. <i>Bipolar Disord</i>. 2006;8(5, pt 2):625-639. doi:10.1111/j.1399-5618.2006.00344.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/17042835/pubmed" id="17042835" target="_blank">17042835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12971013">
<a name="12971013"></a>Bauer M, Adli M, Baethge C, et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. <i>Can J Psychiatry</i>. 2003;48(7):440-448. doi:10.1177/070674370304800703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/12971013/pubmed" id="12971013" target="_blank">12971013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3919911">
<a name="3919911"></a>Bear RA, Sugar L, Paul M. Nephrotic syndrome and renal failure secondary to lithium carbonate therapy. <i>Can Med Assoc J</i>. 1985;132(7):735-737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/3919911/pubmed" id="3919911" target="_blank">3919911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22277970">
<a name="22277970"></a>Bogen DL, Sit D, Genovese A, Wisner KL. Three cases of lithium exposure and exclusive breastfeeding. <i>Arch Womens Ment Health</i>. 2012;15:69-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/22277970/pubmed" id="22277970" target="_blank">22277970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21247849">
<a name="21247849"></a>Broome JT, Solorzano CC. Lithium use and primary hyperparathyroidism. <i>Endocrine Practice</i>. 2011;17:31-35.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/21247849/pubmed" id="21247849" target="_blank">21247849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7259950">
<a name="7259950"></a>Brown EA, Pawlikowski TR. Lithium intoxication treated by peritoneal dialysis. <i>Br J Clin Pract</i>. 1981;35(2):90-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/7259950/pubmed" id="7259950" target="_blank">7259950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16263857">
<a name="16263857"></a>Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. <i>Am J Psychiatry</i>. 2005;162(11):2152-2161. doi:10.1176/appi.ajp.162.11.2152.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/16263857/pubmed" id="16263857" target="_blank">16263857</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Carbolith.1">
<a name="Carbolith.1"></a>Carbolith (lithium carbonate) [product monograph]. Laval, Quebec, Canada: Bausch Health Canada Inc; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24165107">
<a name="24165107"></a>Carter L, Zolezzi M, Lewczyk A. An updated review of the optimal lithium dosage regimen for renal protection. <i>Can J Psychiatry.</i> 2013;58(10):595-600. doi:10.1177/070674371305801009.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/24165107/pubmed" id="24165107" target="_blank">24165107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23814104">
<a name="23814104"></a>Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. <i>BMJ</i>. 2013;346:f3646. doi:10.1136/bmj.f3646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/23814104/pubmed" id="23814104" target="_blank">23814104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16199826">
<a name="16199826"></a>Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. <i>Am J Psychiatry</i>. 2005;162(10):1805-1819. doi:10.1176/appi.ajp.162.10.1805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/16199826/pubmed" id="16199826" target="_blank">16199826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25969470">
<a name="25969470"></a>Cleare A, Pariante CM, Young AH, et al; Members of the Consensus Meeting. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. <i>J Psychopharmacol</i>. 2015;29(5):459-525. doi:10.1177/0269881115581093.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/25969470/pubmed" id="25969470" target="_blank">25969470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1769139">
<a name="1769139"></a>Clericetti N, Beretta-Piccoli C. Lithium clearance in patients with chronic renal diseases. <i>Clin Nephrol</i>. 1991;36(6):281-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/1769139/pubmed" id="1769139" target="_blank">1769139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30390660">
<a name="30390660"></a>Davis J, Desmond M, Berk M. Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification. <i>BMC Nephrol</i>. 2018;19(1):305. doi:10.1186/s12882-018-1101-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/30390660/pubmed" id="30390660" target="_blank">30390660</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30748087">
<a name="30748087"></a>Engels N, van Alphen AM, Bosch TM, Hoekstra R. Successful lithium treatment in a patient on hemodialysis. <i>Bipolar Disord</i>. 2019;21(3):285-287. doi:10.1111/bdi.12756<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/30748087/pubmed" id="30748087" target="_blank">30748087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21663422">
<a name="21663422"></a>Findling RL, Kafantaris V, Pavuluri M, et al. Dosing strategies for lithium monotherapy in children and adolescents with bipolar I disorder. <i>J Child Adolesc Psychopharmacol</i>. 2011;21(3):195-205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/21663422/pubmed" id="21663422" target="_blank">21663422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23510444">
<a name="23510444"></a>Findling RL, Kafantaris V, Pavuluri M, et al. Post-acute effectiveness of lithium in pediatric bipolar I disorder. <i>J Child Adolesc Psychopharmacol</i>. 2013;23(2):80-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/23510444/pubmed" id="23510444" target="_blank">23510444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20531219">
<a name="20531219"></a>Findling RL, Landersdorfer CB, Kafantaris V, et al. First-dose pharmacokinetics of lithium carbonate in children and adolescents. <i>J Clin Psychopharmacol.</i> 2010;30(4):404-410. doi:10.1097/JCP.0b013e3181e66a62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/20531219/pubmed" id="20531219" target="_blank">20531219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26459650">
<a name="26459650"></a>Findling RL, Robb A, McNamara NK, et al. Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. <i>Pediatrics</i>. 2015;136(5):885-894.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/26459650/pubmed" id="26459650" target="_blank">26459650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28576914">
<a name="28576914"></a>Foulser P, Abbasi Y, Mathilakath A, Nilforooshan R. Do not treat the numbers: lithium toxicity. <i>BMJ Case Rep</i>. 2017;2017:bcr2017220079. doi:10.1136/bcr-2017-220079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/28576914/pubmed" id="28576914" target="_blank">28576914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gal.2007">
<a name="Gal.2007"></a>Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30102627">
<a name="30102627"></a>Gao K, Goto T, Yuan C, et al. A pilot study of the effectiveness of lithium versus quetiapine immediate release monotherapy in patients with bipolar spectrum disorders. <i>J Clin Psychopharmacol</i>. 2018;38(5):422-434. doi:10.1097/JCP.0000000000000927.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/30102627/pubmed" id="30102627" target="_blank">30102627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32139195">
<a name="32139195"></a>García-Blanco A, García-Portilla MP, Fuente-Tomás L, et al. Sexual dysfunction and mood stabilizers in long-term stable patients with bipolar disorder. <i>J Sex Med</i>. 2020;17(5):930-940. doi:10.1016/j.jsxm.2020.01.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/32139195/pubmed" id="32139195" target="_blank">32139195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27770296">
<a name="27770296"></a>Girardi P, Brugnoli R, Manfredi G, Sani G. Lithium in bipolar disorder: Optimizing therapy using prolonged-release formulations. <i>Drugs R D</i>. 2016;16(4):293-302. doi:10.1007/s40268-016-0139-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/27770296/pubmed" id="27770296" target="_blank">27770296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gitlin.2021">
<a name="Gitlin.2021"></a>Gitlin M. Unipolar depression in adults: Treatment with lithium. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a> Accessed March 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27900734">
<a name="27900734"></a>Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. <i>Int J Bipolar Disord</i>. 2016;4(1):27. doi:10.1186/s40345-016-0068-y.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/27900734/pubmed" id="27900734" target="_blank">27900734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14726729">
<a name="14726729"></a>Gracious BL, Findling RL, Seman C, Youngstrom EA, Demeter CA, Calabrese JR. Elevated thyrotropin in bipolar youths prescribed both lithium and divalproex sodium. <i>J Am Acad Child Adolesc Psychiatry</i>. 2004;43(2):215-220.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/14726729/pubmed" id="14726729" target="_blank">14726729</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19453201">
<a name="19453201"></a>Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. <i>CNS Drugs</i>. 2009;23:397-418.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/19453201/pubmed" id="19453201" target="_blank">19453201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19347775">
<a name="19347775"></a>Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania [published correction appears in <i>World J Biol Psychiatry</i>. 2009;10(3):255]. <i>World J Biol Psychiatry</i>. 2009;10(2):85-116. doi:10.1080/15622970902823202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/19347775/pubmed" id="19347775" target="_blank">19347775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20148751">
<a name="20148751"></a>Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. <i>World J Biol Psychiatry</i>. 2010;11(2):81-109. doi:10.3109/15622970903555881.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/20148751/pubmed" id="20148751" target="_blank">20148751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31369795">
<a name="31369795"></a>Hafeman DM, Rooks B, Merranko J, et al. Lithium versus other mood-stabilizing medications in a longitudinal study of youth diagnosed with bipolar disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(10):1146-1155. doi:10.1016/j.jaac.2019.06.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/31369795/pubmed" id="31369795" target="_blank">31369795</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36472471">
<a name="36472471"></a>Hobbs E, Reed R, Lorberg B, Robb AS, Dorfman J. Psychopharmacological treatment algorithms of manic/mixed and depressed episodes in pediatric bipolar disorder. <i>J Child Adolesc Psychopharmacol</i>. 2022;32(10):507-521. doi:10.1089/cap.2022.0035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/36472471/pubmed" id="36472471" target="_blank">36472471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19287551">
<a name="19287551"></a>Jafferany M. Lithium and psoriasis: what primary care and family physicians should know. <i>Prim Care Companion J Clin Psychiatry</i>. 2008;10(6):435-439. doi:10.4088/pcc.v10n0602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/19287551/pubmed" id="19287551" target="_blank">19287551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janicak.2020">
<a name="Janicak.2020"></a>Janicak PG. Bipolar disorder in adults and lithium: Pharmacology, administration, and management of adverse effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10789300">
<a name="10789300"></a>Johnston AM, Eagles JM. Lithium-associated clinical hypothyroidism. Prevalence and risk factors. <i>Br J Psychiatry</i>. 1999;175:336-339.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/10789300/pubmed" id="10789300" target="_blank">10789300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2805595">
<a name="2805595"></a>Kamper AL, Holstein-Rathlou NH, Leyssac PP, Strandgaard S. Lithium clearance in chronic nephropathy. <i>Clin Sci (Lond)</i>. 1989;77(3):311-318. doi:10.1042/cs0770311<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/2805595/pubmed" id="2805595" target="_blank">2805595</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28274352">
<a name="28274352"></a>Kazandjieva J, Tsankov N. Drug-induced acne. <i>Clin Dermatol</i>. 2017;35(2):156-162. doi:10.1016/j.clindermatol.2016.10.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/28274352/pubmed" id="28274352" target="_blank">28274352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486148">
<a name="27486148"></a>Kennedy SH, Lam RW, McIntyre RS, et al; CANMAT Depression Work Group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments [published correction appears in <i>Can J Psychiatry</i>. 2017;62(5):356]. <i>Can J Psychiatry</i>. 2016;61(9):540-560. doi:10.1177/0706743716659417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/27486148/pubmed" id="27486148" target="_blank">27486148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23391071">
<a name="23391071"></a>Kibirige D, Luzinda K, Ssekitoleko R. Spectrum of lithium induced thyroid abnormalities: a current perspective. <i>Thyroid Res</i>. 2013;6(1):3. doi:10.1186/1756-6614-6-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/23391071/pubmed" id="23391071" target="_blank">23391071</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2016">
<a name="Kliegman.2016"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kupka.2020">
<a name="Kupka.2020"></a>Kupka R. Rapid cycling bipolar disorder in adults: Treatment of major depression. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22985484">
<a name="22985484"></a>Lehmann SW, Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: what do we know? <i>J Affect Disord</i>. 2013;146(2):151-157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/22985484/pubmed" id="22985484" target="_blank">22985484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31670617">
<a name="31670617"></a>Lieber I, Ott M, Öhlund L, et al. Lithium-associated hypothyroidism and potential for reversibility after lithium discontinuation: Findings from the LiSIE retrospective cohort study. <i>J Psychopharmacol</i>. 2020;34(3):293-303. doi:10.1177/0269881119882858<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/31670617/pubmed" id="31670617" target="_blank">31670617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lithane.1">
<a name="Lithane.1"></a>Lithane (lithium carbonate) capsules, USP [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lithium.2019.12">
<a name="Lithium.2019.12"></a>Lithium carbonate capsules (lithium carbonate) [prescribing information]. Piscataway, NJ: Camber Pharmaceuticals, Inc; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LithiumCapsTabs.2020.10">
<a name="LithiumCapsTabs.2020.10"></a>Lithium carbonate tablets and capsules and lithium oral solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lithiumsyrup.1">
<a name="Lithiumsyrup.1"></a>Lithium citrate syrup [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc; December 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LithiumER.2022.07">
<a name="LithiumER.2022.07"></a>Lithium extended-release 450 mg tablets [prescribing information]. Eatontown, NJ: West-Ward; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-LithiumER.2015.07">
<a name="LithiumER.2015.07"></a>Lithium extended-release 450 mg tablets [prescribing information]. Pulaski, TN: AvKARE; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lithmax.1">
<a name="Lithmax.1"></a>Lithmax (lithium carbonate) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; December 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lithobid.2020.01">
<a name="Lithobid.2020.01"></a>Lithobid (lithium carbonate, USP) [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34176305">
<a name="34176305"></a>McGrane IR, Omar FA, Morgan NF, Shuman MD. Lithium therapy in patients on dialysis: a systematic review. <i>Int J Psychiatry Med</i>. 2021:912174211028544. doi:10.1177/00912174211028544<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/34176305/pubmed" id="34176305" target="_blank">34176305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22265699">
<a name="22265699"></a>McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. <i>Lancet</i>. 2012;379(9817):721-728.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/22265699/pubmed" id="22265699" target="_blank">22265699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25853371">
<a name="25853371"></a>Meehan AD, Humble MB, Yazarloo P, Järhult J, Wallin G. The prevalence of lithium-associated hyperparathyroidism in a large Swedish population attending psychiatric outpatient units. <i>J Clin Psychopharmacol</i>. 2015;35(3):279-285. doi:10.1097/JCP.0000000000000303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/25853371/pubmed" id="25853371" target="_blank">25853371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mehrizi.2012">
<a name="Mehrizi.2012"></a>Mehrizi M, Fontem RF, Gearhart TR, Pascuzzi RM. <i>Medications and Myasthenia Gravis (a Reference for Health Care Professionals)</i>. Indiana University School of Medicine's Department of Neurology; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29247520">
<a name="29247520"></a>Mehta N, Vannozzi R. Lithium-induced electrocardiographic changes: a complete review. <i>Clin Cardiol</i>. 2017;40(12):1363-1367.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/29247520/pubmed" id="29247520" target="_blank">29247520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24910829">
<a name="24910829"></a>Mir SA, Wani AI, Masoodi SR, Bashir MI, Ahmad N. Lithium toxicity and myxedema crisis in an elderly patient. <i>Indian J Endocrinol Metab</i>. 2013;17(suppl 3):S654-S656. doi:10.4103/2230-8210.123558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/24910829/pubmed" id="24910829" target="_blank">24910829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11564052">
<a name="11564052"></a>Mitchell PB. Therapeutic drug monitoring of psychotropic medications. <i>Br J Clin Pharmacol</i>. 2001;52(suppl 1):45S-54S. doi: 10.1046/j.1365-2125.2001.0520s1045.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/11564052/pubmed" id="11564052" target="_blank">11564052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. https://www.nice.org.uk/guidance/ng222. Published June 29, 2022. Accessed February 6, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25069082">
<a name="25069082"></a>Nelson JC, Baumann P, Delucchi K, Joffe R, Katona C. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. <i>J Affect Disord</i>. 2014;168:269-275.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/25069082/pubmed" id="25069082" target="_blank">25069082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28135844">
<a name="28135844"></a>Nelson JC, Spyker DA. Morbidity and mortality associated with medications used in the treatment of depression: an analysis of cases reported to U.S. poison control centers, 2000-2014. <i>Am J Psychiatry</i>. 2017;174(5):438-450. doi:10.1176/appi.ajp.2016.16050523.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/28135844/pubmed" id="28135844" target="_blank">28135844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16263858">
<a name="16263858"></a>Newport DJ, Viguera AC, Beach AJ, et al. Lithium placental passage and obstetrical outcome: Implications for clinical management during late pregnancy. <i>Am J Psychiatry.</i> 2005;162(11):2162-2170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/16263858/pubmed" id="16263858" target="_blank">16263858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29346806">
<a name="29346806"></a>Nielsen RE, Kessing LV, Nolen WA, Licht RW. Lithium and renal impairment: A review on a still hot topic. <i>Pharmacopsychiatry</i>. 2018;51(5):200-205. doi:10.1055/s-0043-125393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/29346806/pubmed" id="29346806" target="_blank">29346806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16946176">
<a name="16946176"></a>Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. <i>Am J Psychiatry</i>. 2006;163(9):1519-1530; quiz 1665. doi:10.1176/ajp.2006.163.9.1519<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/16946176/pubmed" id="16946176" target="_blank">16946176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24991789">
<a name="24991789"></a>Oruch R, Elderbi MA, Khattab HA, Pryme IF, Lund A. Lithium: a review of pharmacology, clinical uses, and toxicity. <i>Eur J Pharmacol</i>. 2014;740:464-473. doi:10.1016/j.ejphar.2014.06.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/24991789/pubmed" id="24991789" target="_blank">24991789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31007893">
<a name="31007893"></a>Ott M, Forssén B, Werneke U. Lithium treatment, nephrogenic diabetes insipidus and the risk of hypernatraemia: a retrospective cohort study. <i>Ther Adv Psychopharmacol</i>. 2019;9:2045125319836563. doi:10.1177/2045125319836563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/31007893/pubmed" id="31007893" target="_blank">31007893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16540813">
<a name="16540813"></a>Patel NC, Delbello MP, Bryan HS, et al. Open-label lithium for the treatment of adolescents with bipolar depression. <i>J Am Acad Child Psychiatry.</i> 2006;45(3):289-297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/16540813/pubmed" id="16540813" target="_blank">16540813</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Post.2020">
<a name="Post.2020"></a>Post RM. Bipolar disorder in adults: Choosing maintenance treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32489731">
<a name="32489731"></a>Rauf A, Gul S, Nasir M, Arif U, Oyenuga M. A rare case of lithium-induced partial nephrogenic diabetes insipidus. <i>Cureus</i>. 2020;12(4):e7877. doi:10.7759/cureus.7877<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/32489731/pubmed" id="32489731" target="_blank">32489731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32850223">
<a name="32850223"></a>Ravi V, Serafini NJ, Pulipati P, Trohman R, Sharma PS. Lithium-induced Brugada pattern: A case report and review of literature. <i>Cureus</i>. 2020;12(7):e9351. doi:10.7759/cureus.9351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/32850223/pubmed" id="32850223" target="_blank">32850223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25519823">
<a name="25519823"></a>Rej S, Elie D, Mucsi I, Looper KJ, Segal M. Chronic kidney disease in lithium-treated older adults: a review of epidemiology, mechanisms, and implications for the treatment of late-life mood disorders. <i>Drugs Aging</i>. 2015;32(1):31-42. doi:10.1007/s40266-014-0234-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/25519823/pubmed" id="25519823" target="_blank">25519823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19265637">
<a name="19265637"></a>Sanacora G. New understanding of mechanisms of action of bipolar medications. <i>J Clin Psychiatry</i>. 2008;69(suppl 5):22-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/19265637/pubmed" id="19265637" target="_blank">19265637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19252941">
<a name="19252941"></a>Saunders BD, Saunders EF, Gauger PG. Lithium therapy and hyperparathyroidism: an evidence-based assessment. <i>World J Surg</i>. 2009;33(11):2314-23. doi:10.1007/s00268-009-9942-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/19252941/pubmed" id="19252941" target="_blank">19252941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23713068">
<a name="23713068"></a>Scarfi F, Arunachalam M. Lithium acne. <i>CMAJ</i>. 2013;185(17):1525. doi:10.1503/cmaj.130009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/23713068/pubmed" id="23713068" target="_blank">23713068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31837914">
<a name="31837914"></a>Schoot TS, Molmans THJ, Grootens KP, Kerckhoffs APM. Systematic review and practical guideline for the prevention and management of the renal side effects of lithium therapy. <i>Eur Neuropsychopharmacol</i>. 2020;31:16-32. doi:10.1016/j.euroneuro.2019.11.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/31837914/pubmed" id="31837914" target="_blank">31837914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19884236">
<a name="19884236"></a>Sharma V, Burt VK, Ritchie HL. Bipolar II postpartum depression: Detection, diagnosis, and treatment. <i>Am J Psychiatry</i>. 2009;166:1217-1221.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/19884236/pubmed" id="19884236" target="_blank">19884236</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20657135">
<a name="20657135"></a>Shreedhar KB, Madhukara J, Jessy J, Manohari SM, Srinivasan K. Drug hypersensitivity syndrome with lithium. <i>Indian J Dermatol Venereol Leprol</i>. 2010;76(4):426-427. doi:10.4103/0378-6323.66600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/20657135/pubmed" id="20657135" target="_blank">20657135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7097954">
<a name="7097954"></a>Shukla VR, Borison RL. Lithium and lupuslike syndrome. <i>JAMA</i>. 1982;248(8):921-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/7097954/pubmed" id="7097954" target="_blank">7097954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20592663">
<a name="20592663"></a>Singh LK, Nizamie SH, Akhtar S, Praharaj SK. Improving tolerability of lithium with a once-daily dosing schedule. <i>Am J Ther</i>. 2011;18(4):288-291. doi: 10.1097/MJT.0b013e3181d070c3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/20592663/pubmed" id="20592663" target="_blank">20592663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8149115">
<a name="8149115"></a>Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. <i>Br J Psychiatry</i>. 1993;162:634-640. doi:10.1192/bjp.162.5.634.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/8149115/pubmed" id="8149115" target="_blank">8149115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stovall.2021">
<a name="Stovall.2021"></a>Stovall J. Bipolar mania and hypomania in adults: Choosing pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 10, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31242784">
<a name="31242784"></a>Sun AY, Woods S, Findling RL, Stepanova E. Safety considerations in the psychopharmacology of pediatric bipolar disorder. <i>Expert Opin Drug Saf</i>. 2019;18(9):777-794. doi:10.1080/14740338.2019.1637416<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/31242784/pubmed" id="31242784" target="_blank">31242784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18358540">
<a name="18358540"></a>Suppes T, Marangell LB, Bernstein IH, et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. <i>J Affect Disord</i>. 2008;111(2-3):334-343. doi:10.1016/j.jad.2008.02.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/18358540/pubmed" id="18358540" target="_blank">18358540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31741184">
<a name="31741184"></a>Tan MG, Worley B, Kim WB, Ten Hove M, Beecker J. Drug-induced intracranial hypertension: A systematic review and critical assessment of drug-induced causes. <i>Am J Clin Dermatol</i>. 2020;21(2):163-172. doi:10.1007/s40257-019-00485-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/31741184/pubmed" id="31741184" target="_blank">31741184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21281855">
<a name="21281855"></a>Thomas T, Stansifer L, Findling RL. Psychopharmacology of pediatric bipolar disorders in children and adolescents. <i>Pediatr Clin North Am</i>. 2011;58(1):173-xii.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/21281855/pubmed" id="21281855" target="_blank">21281855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VaDoD2019">
<a name="VaDoD2019"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the assessment and management of patients as risk for suicide. <a href="https://www.healthquality.va.gov/guidelines/MH/srb/VADoDSuicideRiskFullCPGFinal5088919.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/srb/VADoDSuicideRiskFullCPGFinal5088919.pdf</a>. Updated May 2019. Accessed March 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VaDoD2022">
<a name="VaDoD2022"></a>US Department of Veterans Affairs/US Department of Defense. VA/DoD clinical practice guideline for the management of major depressive disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPGFinal508.pdf</a>. Published 2022. Accessed May 8, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17267800">
<a name="17267800"></a>Viguera AC, Newport DJ, Ritchie J, et al. Lithium in breast milk and nursing infants: clinical implications. <i>Am J Psychiatry</i>. 2007;164:342-345.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/17267800/pubmed" id="17267800" target="_blank">17267800</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32457664">
<a name="32457664"></a>Volkmann C, Bschor T, Köhler S. Lithium treatment over the lifespan in bipolar disorders. <i>Front Psychiatry</i>. 2020;11:377. doi:10.3389/fpsyt.2020.00377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/32457664/pubmed" id="32457664" target="_blank">32457664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8006194">
<a name="8006194"></a>Ward ME, Musa MN, Bailey L. Clinical pharmacokinetics of lithium. <i>J Clin Pharmacol</i>. 1994;34:280-285.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/8006194/pubmed" id="8006194" target="_blank">8006194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5090765">
<a name="5090765"></a>Wilson JH, Donker AJ, van der Hem GK, Wientjes J. Peritoneal dialysis for lithium poisoning. <i>Br Med J</i>. 1971;2(5764):749-750. doi:10.1136/bmj.2.5764.749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/5090765/pubmed" id="5090765" target="_blank">5090765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536616">
<a name="29536616"></a>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disord</i>. 2018;20(2):97-170. doi:10.1111/bdi.12609.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/29536616/pubmed" id="29536616" target="_blank">29536616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21422871">
<a name="21422871"></a>Yonkers KA, Vigod S, Ross LE. Diagnosis, pathophysiology, and management of mood disorders in pregnant and postpartum women. <i>Obstet Gynecol.</i> 2011;117:961-977.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/21422871/pubmed" id="21422871" target="_blank">21422871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lithium-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9566 Version 437.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
